Cannabis (Cannabis sativa)

Cannabis sativa contains primary bioactive compounds THC (delta-9-tetrahydrocannabinol) and CBD (cannabidiol), which interact with the endocannabinoid system's CB1 and CB2 receptors to modulate pain, inflammation, and mood. THC produces psychoactive effects via CB1 receptor agonism, while CBD exerts anxiolytic and anti-inflammatory effects through multiple non-psychoactive pathways.

Origin & History

Cannabis sativa L. is a flowering plant native to Central Asia, known for containing over 500 chemical compounds, primarily cannabinoids. It is typically extracted using solvent-based methods such as hexane and ethanol to isolate specific compounds or whole-plant preparations.

Historical & Cultural Context

Cannabis has been used traditionally for various purposes, including medicinal and recreational uses, across different cultures globally. In traditional medicine systems, it has been utilized for its psychoactive and therapeutic properties.

Health Benefits

• Pain relief: THC and CBD interact with cannabinoid receptors to modulate pain perception (Preliminary evidence).
• Anti-inflammatory effects: Cannabinoids activate CB2 receptors, reducing inflammation (Preliminary evidence).
• Anxiety reduction: CBD has been found to have anxiolytic effects without psychoactivity (Preliminary evidence).
• Neuroprotective properties: Cannabinoids may protect neurons via MAPK pathway modulation (Preliminary evidence).
• Antioxidant activity: Cannabis flavonoids like quercetin exhibit antioxidant properties (Preliminary evidence).

How It Works

THC acts as a partial agonist at CB1 receptors in the central nervous system and CB2 receptors in peripheral immune tissues, inhibiting adenylyl cyclase and reducing cAMP signaling to dampen pain and inflammatory responses. CBD modulates the endocannabinoid system indirectly by inhibiting fatty acid amide hydrolase (FAAH), the enzyme responsible for degrading the endogenous cannabinoid anandamide, effectively raising anandamide levels. CBD also antagonizes GPR55 receptors, inhibits TRPV1 ion channels involved in pain transduction, and exerts serotonergic effects via 5-HT1A receptor partial agonism, contributing to its anxiolytic and analgesic properties.

Scientific Research

The research does not provide specific clinical trials or meta-analyses with PMIDs related to the health benefits of Cannabis sativa. Further detailed clinical investigation is necessary.

Clinical Summary

A 2018 Cochrane review of 16 RCTs (n=1,750) found moderate-quality evidence that cannabis-based medicines reduced chronic neuropathic pain by at least 30% compared to placebo, though responder rates were modest. CBD-specific trials, including a landmark Phase 3 RCT in pediatric epilepsy (Devinsky et al., 2017, n=120), demonstrated a 38.9% median reduction in convulsive seizures with 20 mg/kg/day CBD, leading to FDA approval of Epidiolex. Observational and small RCT data support short-term benefit for cancer-related pain and chemotherapy-induced nausea, but evidence for anxiety disorders remains preliminary, largely from acute-dosing studies (300–600 mg CBD) rather than long-term trials. Overall, evidence strength varies significantly by condition, with neuropathic pain and treatment-resistant epilepsy having the strongest clinical support.

Nutritional Profile

Cannabis sativa contains a complex array of macronutrients, micronutrients, and bioactive compounds that vary significantly by plant part (seeds vs. flower/leaf). SEEDS (hemp seeds, per 100g): Protein: ~31-33g (complete protein containing all essential amino acids, notably edestin ~65-70% and albumin ~30-35%, high bioavailability); Total fat: ~49g (omega-6 linoleic acid ~28g, omega-3 alpha-linolenic acid ~9g, yielding an omega-6:omega-3 ratio of ~3:1, considered nutritionally favorable; also contains gamma-linolenic acid ~1-4g); Carbohydrates: ~8-10g; Dietary fiber: ~4g. Micronutrients in seeds: Magnesium ~700mg (176% DV), Phosphorus ~1160mg (116% DV), Potassium ~860mg (25% DV), Iron ~8mg (44% DV), Zinc ~7mg (64% DV), Vitamin E (tocopherols) ~90mg, Thiamine (B1) ~1.3mg, Riboflavin (B2) ~0.3mg, Niacin (B3) ~9.2mg. FLOWER/LEAF (medicinal/recreational portions): Macronutrient content is not typically consumed in nutritionally significant quantities via inhalation; oral consumption via edibles varies by preparation. BIOACTIVE COMPOUNDS (primary pharmacological relevance): Phytocannabinoids: Delta-9-tetrahydrocannabinol (THC) ~0.3-30% dry weight depending on cultivar (hemp <0.3%, high-potency strains up to 30%); Cannabidiol (CBD) ~0.1-20% dry weight; Cannabigerol (CBG) ~0.1-1%; Cannabichromene (CBC) ~0.1-0.5%; Cannabinol (CBN) trace amounts in fresh material, increases with degradation; THC-A and CBD-A are precursor acids converted via decarboxylation (heat). Terpenes: Myrcene (~0.1-0.5% dry weight, most abundant), Limonene, Beta-caryophyllene (also a CB2 receptor agonist), Linalool, Pinene, Humulene — collectively contribute to 'entourage effect.' Flavonoids: Cannflavins A and B (unique to Cannabis, anti-inflammatory), quercetin, kaempferol, apigenin. Chlorophyll present in leaf material. Bioavailability notes: Inhalation bioavailability of THC ~10-35% with rapid onset (minutes); oral bioavailability ~4-20% due to first-pass hepatic metabolism converting THC to 11-hydroxy-THC (more potent, slower onset 30-120 min); CBD oral bioavailability ~6-19%, significantly enhanced with high-fat meals (up to 5-fold increase); seed protein digestibility-corrected amino acid score (PDCAAS) estimated ~0.66-0.80.

Preparation & Dosage

The research dossier does not specify clinically studied dosage ranges for different forms of Cannabis sativa. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Turmeric, ginger, black pepper, ashwagandha, omega-3

Safety & Interactions

THC commonly causes dose-dependent side effects including tachycardia, dry mouth, impaired short-term memory, dizziness, and psychomotor impairment; long-term heavy use is associated with cannabis use disorder in approximately 9% of users and potential cognitive effects in adolescents. CBD is generally better tolerated but can cause fatigue, diarrhea, and elevated liver enzymes, particularly at high doses (>20 mg/kg/day), and hepatotoxicity risk increases when combined with valproate. Both THC and CBD are potent inhibitors of cytochrome P450 enzymes CYP3A4 and CYP2C9, raising plasma levels of drugs such as warfarin, clobazam, and certain immunosuppressants — requiring clinical monitoring. Cannabis is contraindicated in pregnancy due to associations with low birth weight and neurodevelopmental effects, and is inadvisable in individuals with a personal or family history of psychosis, as THC exposure may precipitate psychotic episodes.